|
1
|
Bokemeyer C, Bondarenko I, Makhson A,
Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G,
Stroh C, et al: Fluorouracil, leucovorin, and oxaliplatin with and
without cetuximab in the first-line treatment of metastatic
colorectal cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ciardiello F, Tejpar S and Papamichael D:
Implications of KRAS mutation status for the treatment of
metastatic colorectal cancer. Target Oncol. 4:311–322. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Roock W, Piessevaux H, De Schutter J,
Janssens M, De Hertogh G, Personeni N, Biesmans B, Van Laethem JL,
Peeters M, Humblet Y, et al: KRAS wild-type state predicts survival
and is associated to early radiological response in metastatic
colorectal cancer treated with cetuximab. Ann Oncol. 19:508–515.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Harbison CT, Horak CE, Ledeine JM,
Mukhopadhyay P, Malone DP, O'Callaghan C, Jonker DJ, Karapetis CS,
Khambata-Ford S, Gustafson N, et al: Validation of companion
diagnostic for detection of mutations in codons 12 and 13 of the
KRAS gene in patients with metastatic colorectal cancer: analysis
of the NCIC CTG CO.17 trial. Arch Pathol Lab Med. 137:820–827.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jonker DJ, O'Callaghan CJ, Karapetis CS,
Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et
al: Cetuximab for the treatment of colorectal cancer. N Engl J Med.
357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Khan IH, Krishnan VV, Ziman M, Janatpour
K, Wun T, Luciw PA and Tuscano J: A comparison of multiplex
suspension array large-panel kits for profiling cytokines and
chemokines in rheumatoid arthritis patients. Cytometry B Clin
Cytom. 76:159–168. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kimura H, Fujiwara Y, Sone T, Kunitoh H,
Tamura T, Kasahara K and Nishio K: High sensitivity detection of
epidermal growth factor receptor mutations in the pleural effusion
of non-small cell lung cancer patients. Cancer Sci. 97:642–648.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ahle JD, Barr S, Chin AM and Battersby TR:
Sequence determination of nucleic acids containing
5-methylisocytosine and isoguanine: identification and insight into
polymerase replication of the non-natural nucleobases. Nucleic
Acids Res. 33:3176–3184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Whitehall V, Tran K, Umapathy A, Grieu F,
Hewitt C, Evans TJ, Ismail T, Li WQ, Collins P, Ravetto P, et al: A
multicenter blinded study to evaluate KRAS mutation testing
methodologies in the clinical setting. J Mol Diagn. 11:543–552.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Conde E, Angulo B, Tang M, Morente M,
Torres-Lanzas J, Lopez-Encuentra A, Lopez-Rios F and
Sanchez-Cespedes M: Molecular context of the EGFR mutations:
evidence for the activation of mTOR/S6K signaling. Clin Cancer Res.
12:710–717. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fernandez P, Carretero J, Medina PP,
Jimenez AI, Rodriguez-Perales S, Paz MF, Cigudosa JC, Esteller M,
Lombardia L, Morente M, et al: Distinctive gene expression of human
lung adenocarcinomas carrying LKB1 mutations. Oncogene.
23:5084–5091. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Landis JR and Koch GG: The measurement of
observer agreement for categorical data. Biometrics. 33:159–174.
1977. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sorich MJ, Wiese MD, Rowland A,
Kichenadasse G, McKinnon RA and Karapetis CS: Extended RAS
mutations and anti-EGFR monoclonal antibody survival benefit in
metastatic colorectal cancer: a meta-analysis of randomized,
controlled trials. Ann Oncol. 26:13–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Angulo B, García-García E, Martínez R,
Suárez-Gauthier A, Conde E, Hidalgo M and López-Ríos F: A
commercial real-time PCR kit provides greater sensitivity than
direct sequencing to detect KRAS mutations: a morphology-based
approach in colorectal carcinoma. J Mol Diagn. 12:292–299. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Franklin WA, Haney J, Sugita M, Bemis L,
Jimeno A and Messersmith WA: KRAS mutation: comparison of testing
methods and tissue sampling techniques in colon cancer. J Mol
Diagn. 12:43–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tol J, Dijkstra JR, Vink-Börger ME,
Nagtegaal ID, Punt CJ, Van Krieken JH and Ligtenberg MJ: High
sensitivity of both sequencing and real-time PCR analysis of KRAS
mutations in colorectal cancer tissue. J Cell Mol Med.
14:2122–2131. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: the PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Peeters M, Price TJ, Cervantes A, Sobrero
AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, et al:
Randomized phase III study of panitumumab with fluorouracil,
leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as
second-line treatment in patients with metastatic colorectal
cancer. J Clin Oncol. 28:4706–4713. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Asaka S, Arai Y, Nishimura Y, Yamaguchi K,
Ishikubo T, Yatsuoka T, Tanaka Y and Akagi K: Microsatellite
instability-low colorectal cancer acquires a KRAS mutation during
the progression from Dukes' A to Dukes' B. Carcinogenesis.
30:494–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Russo A, Rizzo S, Bronte G, Silvestris N,
Colucci G, Gebbia N, Bazan V and Fulfaro F: The long and winding
road to useful predictive factors for anti-EGFR therapy in
metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology.
77(Suppl 1): S57–S68. 2009. View Article : Google Scholar
|
|
25
|
Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ,
Kussie P and Ferguson KM: Structural basis for inhibition of the
epidermal growth factor receptor by cetuximab. Cancer Cell.
7:301–311. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
de Gonzalez Castro D, Angulo B, Gomez B,
Mair D, Martinez R, Suarez-Gauthier A, Shieh F, Velez M, Brophy VH,
Lawrence HJ and Lopez-Rios F: A comparison of three methods for
detecting KRAS mutations in formalin-fixed colorectal cancer
specimens. Br J Cancer. 107:345–351. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jimeno A, Messersmith WA, Hirsch FR,
Franklin WA and Eckhardt SG: KRAS mutations and sensitivity to
epidermal growth factor receptor inhibitors in colorectal cancer:
practical application of patient selection. J Clin Oncol.
27:1130–1136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Srinivasan M, Sedmak D and Jewell S:
Effect of fixatives and tissue processing on the content and
integrity of nucleic acids. Am J Pathol. 161:1961–1971. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yokota T, Shibata N, Ura T, Takahari D,
Shitara K, Muro K and Yatabe Y: Cycleave polymerase chain reaction
method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma
viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene
homolog B1 (BRAF) genotyping in colorectal cancer. Transl Res.
156:98–105. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De Roock W, Jonker DJ, Di Nicolantonio F,
Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M,
Piessevaux H, et al: Association of KRAS p.G13D mutation with
outcome in patients with chemotherapy-refractory metastatic
colorectal cancer treated with cetuximab. JAMA. 304:1812–1820.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bokemeyer C, Kohne C-H, Ciardiello F, et
al: Treatment outcome according to tumor RAS mutation status in
OPUS study patients with metastatic colorectal cancer (mCRC)
randomized to FOLFOX4 with/without cetuximab. ASCO Meeting
Abstracts. 32:35052014.
|
|
32
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
